Some studies have found that HER2+ breast cancer usually has higher levels of stromal tumor-infiltrating lymphocytes (TIL) than HR+/HER2– breast cancer, implying that HER2+ disease is usually more immunogenic. The gene discussed is ERBB2; the disease is breast carcinoma.